Anika Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-17$16.00 RISE2026-04-29$12.39 PEAK2026-05-14$15.34 27d | -22.6% 12d | Missed | Missed | — | — | +23.8% 15d | Missed |
DROP2025-07-25$11.50 RISE2025-11-20$9.30 PEAK2026-02-19$10.70 209d | -19.1% 118d | Missed | Missed | — | — | +15.1% 91d | Missed |
DROP2025-03-20$15.62 RISE2025-07-30$8.10 PEAK2025-10-21$9.78 215d | -48.1% 132d | Missed | Missed | — | — | +20.7% 83d | Missed |
DROP2024-08-30$25.70 RISE2025-01-10$15.57 PEAK2025-02-05$17.97 159d | -39.4% 133d | Missed | Missed | — | — | +15.4% 26d | Missed |
DROP2023-06-12$27.65 RISE2023-09-18$16.98 PEAK2023-12-04$22.75 175d | -38.6% 98d | Missed | Missed | — | — | +34.0% 77d | Missed |
DROP2022-03-02$32.89 RISE2022-06-13$20.46 PEAK2022-08-03$24.68 154d | -37.8% 103d | Missed | Missed | — | — | +20.6% 51d | Missed |
DROP2021-12-29$36.89 RISE2022-05-09$20.40 PEAK2022-08-03$24.68 217d | -44.7% 131d | Missed | Missed | — | — | +21.0% 86d | Missed |
DROP2021-06-01$48.08 RISE2021-09-21$38.75 PEAK2021-11-05$45.03 157d | -19.4% 112d | Missed | Missed | — | — | +16.2% 45d | Missed |
DROP2021-01-07$45.96 RISE2021-03-08$32.49 PEAK2021-06-01$48.08 145d | -29.3% 60d | Missed | Missed | — | — | +48.0% 85d | Missed |
DROP2020-10-12$38.92 RISE2020-11-06$32.59 PEAK2021-01-07$45.96 87d | -16.3% 25d | Missed | Missed | — | — | +41.0% 62d | Missed |
DROP2020-07-01$38.57 RISE2020-09-23$32.56 PEAK2020-12-17$42.04 169d | -15.6% 84d | Missed | Missed | — | — | +29.1% 85d | Missed |
DROP2020-01-06$54.06 RISE2020-05-13$28.95 PEAK2020-07-01$38.57 177d | -46.4% 128d | Missed | Missed | — | — | +33.2% 49d | Missed |
DROP2020-01-06$54.06 RISE2020-03-18$22.38 PEAK2020-06-08$37.28 154d | -58.6% 72d | Missed | Missed | — | — | +66.6% 82d | Missed |
No scored news yet for a sentiment trend.
Investors who take an interest in Anika Therapeutics, Inc. ( NASDAQ:ANIK ) should definitely note that the President...
Steve Griffin April 28, 2026 Dear Fellow Anika Stockholder, 2025 was an important year for Anika-one in which we strengthened...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION...
ANIK refocuses on HA-based OA pain and regenerative ortho products; Integrity revenue is surging post-510(k). Click here to read my most recent analysis.
Moby summary of Anika Therapeutics, Inc.'s Q1 2026 earnings call
Anika Therapeutics (NASDAQ:ANIK) reported first-quarter 2026 results highlighting continued momentum in its commercial channel, progress in its hyaluronic acid (HA)-based product pipeline, and early benefits from operational changes aimed at improving profitability and scalability. Commercial chann
Anika Therapeutics beat Q1 2026 estimates with EPS of $0.27 and revenue of $29.61M, driven by strong commercial sales and OEM orders. Shares surged 8.7% in pre-market trading.
Presentation Operator MessageOperator Good morning, ladies and gentlemen, and welcome to the Anika's First Quarter Earnings Conference Call. I will now turn the call over to Mr. Matt Hall,
Anika Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 29.61 million compared to USD 26.17 million a...
BEDFORD, Mass. — BEDFORD, Mass. — Anika Therapeutics Inc. on Wednesday reported a loss of $5.1 million in its first quarter. The Bedford, Massachusetts-based company said it had a loss of 37...
Anika Therapeutics (NASDAQ:ANIK) affirms FY2026 sales outlook from $114.000 million-$122.500 million to $114.000 million-$122.500 million vs $117.220 million estimate.
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.16) by 268.75 percent. This is a 550 percent increase over losses of $(0.06) per share from
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational...
BEDFORD, Mass., April 15, 2026 -- Anika Therapeutics, Inc. , a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026...
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANIK | -2.15% | +1.47% | +51.20% | +30.31% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.12% | +7.18% | +54.64% | +17.63% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 502.2K | $7.28M | 0.01% | Trimmed-2.6% | 2026-03-31 |
| StateStreet | passive | 346.1K | $5.02M | 0.00% | Added+2.8% | 2026-03-31 |
| TwoSigma | quant | 236.1K | $3.42M | 0.00% | Added+1.0% | 2026-03-31 |
| DEShaw | quant | 229.8K | $3.33M | 0.00% | Trimmed-22.9% | 2026-03-31 |
| FidelityFMR | fundamental | 48.1K | $697.75K | 0.00% | Added+44.9% | 2026-03-31 |
| Citadel | multi-strat | 29.2K | $423.82K | 0.00% | Trimmed-49.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | 0.03 | — | — |
| 2026-04-29 | -0.16 | -0.37 | -131.25% |
| 2026-02-26 | 0.02 | 0.31 | +1450.00% |
| 2025-11-05 | 0.02 | 0.04 | +100.00% |
| 2025-07-30 | -0.13 | -0.13 | — |
| 2025-05-09 | 0.09 | -0.06 | -166.67% |
| 2025-03-12 | 0.09 | -0.03 | -133.33% |
| 2024-10-31 | 0.30 | -0.25 | -183.33% |
| 2024-08-08 | 0.20 | 0.17 | -12.82% |
| 2024-05-08 | 0.05 | 0.09 | +80.00% |
| 2024-03-13 | -0.23 | 0.05 | +122.06% |
| 2023-11-02 | -0.35 | — | +100.00% |
| 2023-08-08 | -0.32 | 0.06 | +118.56% |
| 2023-05-09 | -0.32 | -0.36 | -12.50% |
| 2023-03-06 | -0.22 | -0.21 | +3.08% |
| 2022-11-08 | -0.23 | -0.05 | +78.57% |